Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-EUK-(SO3)CY5-MAS3
- Development stage
- Unknown
- Lead developer
- Netherlands Cancer Institute
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
99mTc-EUK-(SO3)CY5-MAS3 is a dual-modality (hybrid) radiopharmaceutical and optical imaging agent designed for the intraoperative detection and surgical guidance of prostate cancer. Developed by the Netherlands Cancer Institute (NKI-AVL), the molecule consists of a PSMA-targeting Glu-urea-Lys (EUK) motif, a sulfonated Cyanine 5 (Cy5) fluorescent dye, and a mercaptoacetyltriglycine (MAS3) chelator for technetium-99m (99mTc). It specifically targets the Prostate-Specific Membrane Antigen (PSMA), also known as glutamate carboxypeptidase II, which is highly overexpressed in prostate cancer cells. The 99mTc component allows for preoperative SPECT/CT imaging and intraoperative radioguidance using a gamma probe, while the fluorescent Cy5 component enables real-time, high-resolution visualization of tumor margins and lymph node metastases during surgery. This hybrid approach aims to improve the accuracy of surgical resection and the detection of occult nodal disease.
- Other names
- 99mTc-labeled PSMA-targeting hybrid tracerPSMA-hybrid tracer99mTc-EUK-(SO3)Cy5-MAS3
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 99mTc-EUK-(SO3)CY5-MAS3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 99mTc-EUK-(SO3)CY5-MAS3.